Placeholder Banner

BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

December 21, 2018

Washington, DC (December 20, 2018) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement applauding passage today by the House of Representatives of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (H.R. 7328). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS).

“Over the past fifteen years, federal biodefense programs and agencies have spurred the creation of dozens of medical countermeasures, in partnership with industry, greatly improving our nation’s capacity to prepare and respond to the countless known and unknown chemical, biological, radiological and nuclear threats facing our nation. Timely reauthorization of federal biodefense legislation is critical to ensuring that these programs and agencies are able to continue fulfilling their vital public health and national security missions.

“I applaud Congresswomen Susan Brooks (R-IN) and Anna G. Eshoo (D-CA), as well as House leadership, for their tireless bipartisan cooperation in advancing this critical legislation. I urge the Senate to consider and pass this legislation at the earliest opportunity to ensure that our nation’s biodefense capabilities are not compromised.”


Discover More
The Biden administration just announced its intent for the United States to join the COVAX vaccine facility, which aims to deliver COVID-19 vaccines to poor and under-developed countries. Dr. Michelle McMurry-Heath, president and CEO of the…
Washington, D.C. (January 20, 2021) — The BiotechnologyInnovation Organization (BIO) and the Low Carbon Fuels Coalition (LCFC) today released the following statement in support of New Mexico Governor Michelle Lujan Grisham’s inclusion of a…
In his last day in office, former President Donald Trump proposed a sweeping change to Medicare’s “Part D” drug benefit. Billed as a demonstration project through the Centers for Medicare and Medicaid Innovation (CMMI), this new policy would allow…